HOTH - Hoth Therapeutics posts confirmatory results from in vivo HT-003 acne study

Hoth Therapeutics ([[HOTH]]) announces positive confirmatory results from in vivo model of HT-003 assets as potential treatment against acne.The model showed that HT-003 reduces the expression of toll-like receptor 2 ((TLR2)), one of the most critical pathways for acne pathophysiology.The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases, the company said."The data also suggests that the HT-003 compounds have the potential for treatment of numerous inflammatory skin diseases," Jonathan Zippin, Hoth's Senior Scientific Advisor said.In addition to the dermatologic application, Hoth is also exploring the potential application of HT-003 assets in inflammatory bowel disorders ((IBDs)), it said.

For further details see:

Hoth Therapeutics posts confirmatory results from in vivo HT-003 acne study